Fig 1. Clinical information for patients with resistance to EGFR tyrosine kinase inhibitor and BRAF fusions. (A) Disease course of patient 2, who was found to have acquired resistance to osimertinib and acylglycerol kinase gene (AGK)/BRAF fusion. (B) Disease course of patient 4, who was found to have acquired resistance to erlotinib and progressive mediastinal disease with AGK/BRAF fusion.
{}